
SHS buys minority stake in Develco Pharma
SHS has acquired a minority stake in Germany-based drug developer Develco Pharma.
The investment is intended to accelerate the company's development of new drugs, according to a statement. New products are likely to focus on new indications and therapeutic areas.
The deal came about via a proprietary connection, with an introduction taking place at the start of 2020, Manfred Ulmer-Weber, partner at SHS, told Unquote: "We were able to meet before the lockdown started and saw that it could be an interesting situation for both parties. Develco is well established and has a strong growth pipeline, and as a specialised healthcare investor, we were able to bring not just money but also value to the table."
Ulmer-Weber is to join Develco's board of directors following the transaction, according to a statement.
SHS is investing via its fifth fund, which held a final close in July 2019 on €130m and has now made nine investments. The vehicle generally deploys equity tickets of up to €30m, with the option to provide up to €60m alongside co-investors. The fund focuses on healthcare, medical technology and diagnostics businesses.
The fund aims to make 12-15 deals in total, Ulmer-Weber said, and he expects the vehicle will make around five more deals in 2021 and 2022: "We are looking for growth cases and buyouts; we still have some dry powder in our fund."
Company
Develco provides development, approval and production of innovative and generic pharmaceutical products. The company also has a modular system of formulation technologies to manufacture orally administered drugs. Develco's client base comprises pharmaceutical companies that sell products on a global scale.
Develco was founded in 2006 and employs 120 staff. It is headquartered in Schopfheim, Germany, and also has operations in Switzerland.
People
SHS – Hubertus Leonhardt (partner, managing director); Manfred Ulmer-Weber (partner).
Develco Pharma – Mathias Scheer (chairman of the board of directors); Martin Renner (CEO).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds